[go: up one dir, main page]

IL134168A0 - Heterocyclic vinylethers against neurological disorders - Google Patents

Heterocyclic vinylethers against neurological disorders

Info

Publication number
IL134168A0
IL134168A0 IL13416898A IL13416898A IL134168A0 IL 134168 A0 IL134168 A0 IL 134168A0 IL 13416898 A IL13416898 A IL 13416898A IL 13416898 A IL13416898 A IL 13416898A IL 134168 A0 IL134168 A0 IL 134168A0
Authority
IL
Israel
Prior art keywords
vinylethers
heterocyclic
neurological disorders
against neurological
disorders
Prior art date
Application number
IL13416898A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL134168A0 publication Critical patent/IL134168A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13416898A 1997-08-14 1998-08-06 Heterocyclic vinylethers against neurological disorders IL134168A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97114065 1997-08-14
PCT/EP1998/004890 WO1999008678A1 (en) 1997-08-14 1998-08-06 Heterocyclic vinylethers against neurological disorders

Publications (1)

Publication Number Publication Date
IL134168A0 true IL134168A0 (en) 2001-04-30

Family

ID=8227219

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13416898A IL134168A0 (en) 1997-08-14 1998-08-06 Heterocyclic vinylethers against neurological disorders

Country Status (24)

Country Link
US (2) US6248901B1 (xx)
EP (1) EP1003505B1 (xx)
JP (1) JP3593031B2 (xx)
KR (1) KR100357650B1 (xx)
CN (1) CN1154489C (xx)
AR (1) AR016604A1 (xx)
AT (1) ATE262331T1 (xx)
AU (1) AU741532B2 (xx)
BR (1) BR9811933A (xx)
CA (1) CA2297732C (xx)
DE (1) DE69822638T2 (xx)
ES (1) ES2216305T3 (xx)
HR (1) HRP20000079A2 (xx)
HU (1) HUP0004412A3 (xx)
ID (1) ID28529A (xx)
IL (1) IL134168A0 (xx)
NO (1) NO20000738L (xx)
NZ (1) NZ502463A (xx)
PL (1) PL192029B1 (xx)
RU (1) RU2218919C2 (xx)
TR (1) TR200000405T2 (xx)
WO (1) WO1999008678A1 (xx)
YU (1) YU6100A (xx)
ZA (1) ZA987145B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ525917A (en) * 2000-12-04 2005-11-25 F Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists and their use in treating mGLuR5 receptor mediated disorders
US20030103995A1 (en) * 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
DE10205057A1 (de) * 2002-02-07 2003-08-14 Bayer Cropscience Ag Substituierte 4-Hetaryl-pyrazoline
BRPI0408136A (pt) 2003-03-07 2006-03-01 Astellas Pharma Inc derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
KR101057032B1 (ko) 2004-06-01 2011-08-16 에프. 호프만-라 로슈 아게 Ｍｇｌｕ5 수용체 길항제로서 피리딘-4-일-에틴일-이미다졸및 피라졸
ITVA20050050A1 (it) * 2005-08-05 2007-02-06 Lamberti Spa Sistemi fotopolimerizzabili contenenti coiniziatori fotoreticolabili a bassa estraibilita' e volatilita'
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
DK2083811T3 (en) 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
KR101148580B1 (ko) 2006-12-21 2012-05-24 에프. 호프만-라 로슈 아게 Ｍｇｌｕｒ5 수용체 길항제의 다형체
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
AU2008297877C1 (en) * 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
DE602008004794D1 (de) * 2007-09-14 2011-03-10 Addex Pharmaceuticals Sa 1',3'-disubstituierte 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-ä1,4'übipyridinyl-2'-one
US8785486B2 (en) * 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
CN102186477B (zh) 2008-10-16 2013-07-17 奥梅-杨森制药有限公司 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
AR076861A1 (es) 2009-05-12 2011-07-13 Addex Pharma Sa Derivados de 1,2,4-triazolo (4,3-a)piridina y su uso como moduladores alostericos positivos de los receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2010130422A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102506473B (zh) * 2011-10-18 2014-06-11 江苏七彩科技有限公司 直接蒸发式冰蓄冷制冷系统及其制冷方法
CN102690240B (zh) * 2012-06-07 2014-09-10 郑州大学 三氮唑烯醚类、肟醚类化合物及其制备方法与应用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
SMT201900545T1 (it) 2014-01-21 2019-11-13 Janssen Pharmaceutica Nv Combinazioni comprendenti modulatori allosterici positivi o agonisti ortosterici del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo
CN106279038A (zh) * 2016-08-16 2017-01-04 湖南中威制药有限公司 一种硝酸奥昔康唑原料药的合成方法
MY199104A (en) * 2016-12-14 2023-10-13 Sk Biopharmaceuticals Co Ltd Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
WO2018111006A1 (ko) * 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
CN118221604A (zh) * 2019-10-24 2024-06-21 爱思开生物制药株式会社 具有改进的选择性的制备芳基2-四唑-2-基酮的方法
KR20230066244A (ko) 2021-11-06 2023-05-15 김경민 점선식 포장지

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330545A (en) * 1977-02-21 1982-05-18 Siegfried Aktiengesellschaft Heterocyclic imidazolyl vinyl ethers and use of same as fungicides or bactericides
DE2839388A1 (de) * 1978-09-11 1980-03-27 Siegfried Ag Imidazolylvinylaether und deren verwendung
CH648552A5 (de) * 1981-01-23 1985-03-29 Siegfried Ag Verfahren zur herstellung von imidazolylvinylethern.
EP0079856A1 (de) * 1981-11-12 1983-05-25 Ciba-Geigy Ag Mikrobizide Triazolyl-vinyläther
DE3417468A1 (de) * 1984-05-11 1985-11-14 Bayer Ag, 5090 Leverkusen Azolylvinylether
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists

Also Published As

Publication number Publication date
JP2001515037A (ja) 2001-09-18
HUP0004412A3 (en) 2003-06-30
PL192029B1 (pl) 2006-08-31
RU2218919C2 (ru) 2003-12-20
AU741532B2 (en) 2001-12-06
US6054588A (en) 2000-04-25
PL338637A1 (en) 2000-11-06
CA2297732A1 (en) 1999-02-25
AR016604A1 (es) 2001-07-25
ID28529A (id) 2001-05-31
KR20010022877A (ko) 2001-03-26
HUP0004412A2 (hu) 2001-07-30
ATE262331T1 (de) 2004-04-15
US6248901B1 (en) 2001-06-19
WO1999008678A1 (en) 1999-02-25
HRP20000079A2 (en) 2000-12-31
AU9159398A (en) 1999-03-08
EP1003505A1 (en) 2000-05-31
TR200000405T2 (tr) 2000-08-21
NO20000738D0 (no) 2000-02-14
ZA987145B (en) 1999-02-15
NO20000738L (no) 2000-04-11
YU6100A (sh) 2002-10-18
ES2216305T3 (es) 2004-10-16
CN1154489C (zh) 2004-06-23
CA2297732C (en) 2008-04-29
DE69822638D1 (de) 2004-04-29
NZ502463A (en) 2002-05-31
DE69822638T2 (de) 2005-02-24
EP1003505B1 (en) 2004-03-24
KR100357650B1 (ko) 2002-10-25
BR9811933A (pt) 2000-09-05
CN1266368A (zh) 2000-09-13
JP3593031B2 (ja) 2004-11-24

Similar Documents

Publication Publication Date Title
IL134168A0 (en) Heterocyclic vinylethers against neurological disorders
AU134107S (en) Eyewear
AU135664S (en) Eyewear
AU133418S (en) Eyewear
GB9715892D0 (en) Heterocyclic compounds
SG129998A1 (en) Compounds possessing neuronal activity
AU137191S (en) Eyewear
PL338797A1 (en) Mill
EP1037631A4 (en) HETEROCYCLIC CATIONIC FATS
AU135669S (en) An eyewear
GB9705071D0 (en) Nebuliser
GB9824714D0 (en) Neurological disorders
GB9824715D0 (en) Neurological disorders
TW333341U (en) Improved eyeglasses
GB9904465D0 (en) Neurological disorders
GB9904468D0 (en) Neurological disorders
EP1011665A4 (en) HETEROCYCLIC AGENTS
CA80283S (en) Eyewear
CA82219S (en) Sunglasses
CA82220S (en) Sunglasses
CA82217S (en) Sunglasses
CA82139S (en) Sunglasses
CA81443S (en) Sunglasses
AU132396S (en) Eyewear
GB9709470D0 (en) Eyewear